APA (7th ed.) Citation

AA, K., HM, A., MKB, B., SM, H., GM, S., A, R., & HA, A. E. (2025). Tailored Intranasal Albumin Caged Selegiline-α Synuclein siRNA Liposome with Improved Efficiency in Parkinson's Model. Pharmaceutics, 17(2), . https://doi.org/10.3390/pharmaceutics17020243

Chicago Style (17th ed.) Citation

AA, Katamesh, Abdel-Bar HM, Break MKB, Hassoun SM, Subaiea GM, Radwan A, and Abo El-Enin HA. "Tailored Intranasal Albumin Caged Selegiline-α Synuclein SiRNA Liposome with Improved Efficiency in Parkinson's Model." Pharmaceutics 17, no. 2 (2025). https://doi.org/10.3390/pharmaceutics17020243.

MLA (9th ed.) Citation

AA, Katamesh, et al. "Tailored Intranasal Albumin Caged Selegiline-α Synuclein SiRNA Liposome with Improved Efficiency in Parkinson's Model." Pharmaceutics, vol. 17, no. 2, 2025, https://doi.org/10.3390/pharmaceutics17020243.